What was the overall market valuation of the US emphysema market in 2024?

The overall market valuation was $2841.3 Million in 2024. Read More

What is the projected market valuation for the US emphysema market by 2035?

The projected valuation for 2035 is $4773.72 Million. Read More

What is the expected CAGR for the US emphysema market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 4.83%. Read More

What are the segment valuations for the treatment of emphysema?

The segment valuations for treatment include medications at $1500.0 - $2500.0 Million, therapy at $800.0 - $1300.0 Million, and surgery at $541.3 - $973.72 Million. Read More

How much is the imaging test segment valued in the diagnosis of emphysema?

The imaging test segment is valued between $850.0 Million and $1400.0 Million. Read More

What is the valuation range for lung function tests in the diagnosis segment?

The valuation range for lung function tests is between $1500.0 Million and $2500.0 Million. Read More

What are the end-user segment valuations for hospitals and clinics in the US emphysema market?

The end-user segment for hospitals and clinics is valued between $1136.52 Million and $1930.56 Million. Read More

What is the valuation range for the panlobular type of emphysema?

The valuation range for the panlobular type is between $1141.3 Million and $1883.72 Million. Read More

What is the projected growth trend for the US emphysema market in the coming years?

The market is expected to grow steadily, reaching a valuation of $4773.72 Million by 2035. Read More

US Emphysema Market

Q: Which companies are considered key players in the US emphysema market?

Key players include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Roche, Teva Pharmaceutical Industries, Mylan, Pfizer, and Merck & Co. Read More

ID: MRFR/Pharma/17378-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Emphysema Market Research Report By Type (centrilobular, panlobular), By Diagnosis (imaging test, lung function test, others, chest X-ray, CT scan), By Treatment (medications, therapy, surgery, smoking cessation drugs, bronchodilators, inhaled steroids, antibiotics, leukotriene modifiers, pulmonary rehabilitation, nutrition therapy, gene therapy, supplemental oxygen, lung volume reduction surgery, lung transplant, bullectomy) and By End-User (hospitals and clinics, surgical centers, others) - Growth & Industry Forecast 2025 To 2035

US Emphysema Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.83%

2024 Market Size$ 2,841.3 Million

2025 Market Size$ 2,978.53 Million

2035 Market Size$ 4,773.72 Million

Key Players

GlaxoSmithKline

Boehringer Ingelheim

AstraZeneca

Novartis

Roche

Teva Pharmaceutical Industries

Trends

Advancements in Treatment Options
Increased Focus on Preventive Care
Integration of Technology in Management

Opportunities

Growing Geriatric Population
Rising Prevalence of Emphysema
Increased Awareness and Education

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Million)
  1. 4.1.1 centrilobular
  2. 4.1.2 panlobular
2. 4.2 Life Sciences, BY Diagnosis (USD Million)
  1. 4.2.1 imaging test
  2. 4.2.2 lung function test
  3. 4.2.3 others
3. 4.3 Life Sciences, BY Treatment (USD Million)
  1. 4.3.1 medications
  2. 4.3.2 therapy
  3. 4.3.3 surgery
4. 4.4 Life Sciences, BY End-User (USD Million)
  1. 4.4.1 hospitals and clinics
  2. 4.4.2 surgical centers
  3. 4.4.3 others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GlaxoSmithKline (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Roche (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Teva Pharmaceutical Industries (IL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Mylan (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Merck & Co. (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY DIAGNOSIS, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY TREATMENT, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY TREATMENT, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Life Sciences Market Segmentation

Life Sciences By Type (USD Million, 2025-2035)

centrilobular
panlobular

Life Sciences By Diagnosis (USD Million, 2025-2035)

imaging test
lung function test
others

Life Sciences By Treatment (USD Million, 2025-2035)

medications
therapy
surgery

Life Sciences By End-User (USD Million, 2025-2035)

hospitals and clinics
surgical centers
others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”